Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer

NCT05025735 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Breast Cancer
HER2-negative Breast Cancer

Interventions

DRUG: Dapagliflozin 10Mg Tab

Sponsor

Saint Luke's Health System

Collaborators

[object Object]